DFN-11 Injection
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medication Overuse Headache
Conditions
Medication Overuse Headache
Trial Timeline
Sep 1, 2015 → Nov 1, 2016
NCT ID
NCT02583425About DFN-11 Injection
DFN-11 Injection is a phase 2 stage product being developed by Dr. Reddy's Laboratories for Medication Overuse Headache. The current trial status is terminated. This product is registered under clinical trial identifier NCT02583425. Target conditions include Medication Overuse Headache.
What happened to similar drugs?
3 of 4 similar drugs in Medication Overuse Headache were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02583425 | Phase 2 | Terminated |
Competing Products
6 competing products in Medication Overuse Headache
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Advagraf + Prograf | Astellas Pharma | Approved | 39 |
| Tacrolimus BID + Advagraf QD | Astellas Pharma | Phase 3 | 36 |
| Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.) + 0.9% natural saline | Johnson & Johnson | Pre-clinical | 22 |
| TasP using ART regimen as per Benin guidelines + PrEP using Truvada | Gilead Sciences | Approved | 43 |
| ziprasidone | Pfizer | Approved | 43 |
| Levetiracetam | UCB | Phase 2 | 35 |